goserelin and Urinary-Retention

Nineteen patients seen for AUR secondary to benign prostate hypertrophy and with high surgical risk, were treated with an LH-RH agonist (GOSERELIN). After six months of treatment a 43.28% decrease in the prostate volume was seen, Improvement, i.e., spontaneous miction, was achieved in 46.6% patients, although post-mictional volumes remained high.

Topics: Acute Disease; Aged; Aged, 80 and over; Goserelin; Humans; Male; Prostatic Hyperplasia; Urinary Retention

A 40-year-old primigravida presented with acute urine retention. Ultrasound examination revealed a large uterine submucosal leiomyoma and GnRH-a was administered. The leiomyoma grew to over twice its original size and protruded through the introitus. After 10 days, it was expelled completely and removed by resectohysteroscopy. The expulsion of the leiomyoma was most likely a result of GnRH-a's flare-up effect.

Topics: Adult; Female; Goserelin; Humans; Leiomyoma; Magnetic Resonance Imaging; Ultrasonography; Urinary Retention; Uterine Neoplasms

A second generation temporary stent (ProstaCoil*) was inserted into the prostatic urethra of patients with obstruction due to prostate cancer to allow spontaneous voiding during hormonal therapy given to decrease the size of the prostatic mass.. The stent was inserted under fluoroscopic guidance using topical anesthesia in 27 patients (mean age 77 years) who presented with urinary retention due to advanced carcinoma of the prostate. All patients underwent operative or nonoperative hormonal therapy shortly after insertion of the stent.. Followup of our patients was 3 to 48 months after stent removal and 15 void spontaneously. In 6 patients the stent was removed 9 to 19 months after insertion due to slow regression of the prostatic mass. Two of these patients required transurethral resection of the prostate and in 3 a new stent was inserted because of recurrent obstruction. two recently treated patients await stent removal and 3 died before removal of the stent. During followup no patient had urinary infection, either with the stent indwelling or after its removal.. Temporary internal stenting of the prostate should be the treatment of choice for relieving obstruction during hormonal therapy given for prostate cancer.

Topics: Aged; Antineoplastic Agents, Hormonal; Catheters, Indwelling; Equipment Design; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Stents; Time Factors; Urethra; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urinary Retention

Thirty-one patients with retention of urine and carcinoma of the prostate were treated with LHRH analogues as primary therapy rather than prostatectomy; 21 patients voided without the need for surgical intervention. Patients presenting in acute retention of urine voided more readily than those presenting in chronic retention, with only 20% requiring surgery. This approach to treatment is safe, efficacious and cost effective.

Topics: Acute Disease; Aged; Chronic Disease; Goserelin; Humans; Male; Prostate; Prostatic Neoplasms; Urinary Retention; Urination

Twelve prostatic hyperplasia patients with total urine retention and, consequently, a permanent catheter, were treated for six months with luteinizing hormone-releasing hormone (LH-RH) analogue having long-term effect. Seven of the 12 patients no longer needed a permanent catheter after the six-month treatment period. Transurethral resection of the prostate was performed for 3 patients. The remaining 2 patients continued to have a catheter. The mean prostatic volume, which was 83 g at the start of the study, fell by 51 percent, to 41 g. Treatment with LH-RH proved to be safe even for patients in poor physical condition, and it also seemed to improve symptoms of prostatic hyperplasia.

Topics: Aged; Aged, 80 and over; Buserelin; Goserelin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Ultrasonography; Urinary Retention